

IN THE CLAIMS

The following is a listing of the claims in the application.

LISTING OF CLAIMS

1 – 17 (Canceled).

18. (Currently Amended) ~~An antibody with binding affinity to a protein according to Claim 1~~ raised against a calcium-binding protein comprising an amino acid sequence encoded by an amino acid sequence shown in SEQ ID NO: 1 or 12.

19. (Original) An antibody according to Claim 18, which is a polyclonal antibody or monoclonal antibody.

20. (Original) A hybridoma which produces a monoclonal antibody according to Claim 19.

21. (Currently Amended) A method for producing a monoclonal antibody ~~with binding affinity to a calcium-binding protein, characterized by culturing a hybridoma producing said monoclonal antibody~~ according to Claim 19, comprising the steps of:

(1) culturing a hybridoma according to claim 20 and

(2) recovering the monoclonal antibody from the culture;

wherein the antibody recognizes a calcium-binding protein comprising an amino acid sequence shown in SEQ ID NO: 19 or 20 (or a calcium-binding protein comprising an amino acid sequence encoded by an amino acid sequence shown in SEQ ID NO: 1 or 12).

22. (currently amended) A diagnostic agent for inflammatory diseases, neoplastic diseases ~~(especially squamous epithelial carcinoma)~~, dermatosis or blood diseases, which comprises an antibody according to Claim 18.

23.(Original) A calcium-binding protein assay reagent comprising an antibody according to Claim 18.

24. (Original) An assay method for calcium-binding protein, characterized by using a reagent according to Claim 23.